All In MedTech

Device Trial Radar · NCT03607825

FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR Extension

ExtracorPoreal FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR EXTension

Last checked: Nov 20, 2026Latest source record: Oct 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

33

Actual

Start

Dec 25, 2018

Primary completion

Jan 11, 2021

Study completion Feb 17, 2021

Sponsor

Lead sponsor
MinnetronixNot on our public-company list
Sponsor type
Industry
First posted
Jul 31, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to further demonstrate safety and characterize effectiveness of the Neurapheresis™ System (extracorporeal system and catheter) to remove red blood cells (RBCs) and lysed blood by-products from hemorrhagic cerebrospinal fluid (CSF) following aneurysmal subarachnoid hemorrhage (aSAH).

Conditions

  • Subarachnoid Hemorrhage

Interventions

  • Neurapheresis SystemDevice

    CSF filtration system and lumbar catheter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Cisternal Blood From Enrollment to Catheter RemovalTime frame: Enrollment to Catheter Removal (Immediately post treatment)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Florida

    Gainesville, Florida

3 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.